Instalab

BMD Z-Score (Left Femoral Neck)

Test
See whether your hip bone is weaker than it should be for your age, before a fracture forces the conversation.

Should you take a BMD Z-Score (Left Femoral Neck) test?

This test is most useful if any of these apply to you.

Worried About Your Bone Strength
You want to know whether your hip bone is keeping pace with peers your age, before a fracture forces the question.
Taking Steroids Long-Term
Chronic prednisone or similar drugs accelerate bone loss; this scan tells you how much damage has accumulated.
Living With Autoimmune Disease
Conditions like rheumatoid arthritis, lupus, and spondyloarthritis raise the odds of low BMD years before fractures appear.
An Athlete Pushing Hard
Endurance athletes, those with menstrual irregularities, or anyone with low body weight can develop bone deficits this scan can catch early.

About BMD Z-Score (Left Femoral Neck)

Your hip is one of the most fracture-prone places in your skeleton, and a break there can rewrite the rest of your life. The Z-score at the left femoral neck answers a sharp question: is the bone at the top of your thigh holding up the way it should for someone your age and sex, or is it quietly falling behind?

This is different from the T-score most people hear about. T-scores compare you to a healthy young adult and are used to label osteoporosis in older patients. Z-scores compare you to your peers and are most useful for younger adults, premenopausal women, and anyone whose bone loss might be driven by something other than normal aging.

What This Measurement Captures

BMD (bone mineral density) at the femoral neck is measured by a low-dose imaging scan called DXA (dual-energy X-ray absorptiometry). The machine quantifies how much mineral is packed into a small slice of bone at the top of your femur. The Z-score is the number of standard deviations your result sits above or below the average for people your age and sex.

The hip bone you are measuring is built and rebuilt constantly by two types of cells: ones that lay down new bone and ones that break it down. When breakdown outpaces buildup, density falls. A low Z-score signals that this balance has tipped against you faster than expected for your age, which often points to an underlying cause worth investigating.

Fracture Risk

Lower femoral neck BMD is one of the strongest predictors of future fracture. In a cohort of older women followed for an average of about 2.7 years, each standard deviation drop in femoral neck BMD raised the risk of a fragility fracture by roughly 77% (hazard ratio 1.77). In a large analysis of 42,198 adults with and without type 2 diabetes, femoral neck BMD was significantly tied to hip, non-spine, and major osteoporotic fracture risk in both groups.

What this means for you: a Z-score that drifts well below zero is not a cosmetic finding. It changes the odds of a hip fracture, vertebral fracture, or wrist break years before any of those happen, which is exactly the point of catching it now.

Heart Disease and Mortality

Bone density connects to outcomes beyond the skeleton. A meta-analysis of prospective cohorts including 46,182 participants found that each standard deviation drop in hip or femoral neck BMD was tied to about 20% higher all-cause mortality (hazard ratio 1.20) and 20% higher cardiovascular mortality (hazard ratio 1.20). In a NHANES analysis of 15,076 adults, having osteoporosis at the femoral neck was associated with roughly 41% higher all-cause mortality compared with normal density.

A pooled analysis of 28 longitudinal studies covering more than 1.1 million people found that lower BMD was tied to a 33% higher risk of incident cardiovascular disease (hazard ratio 1.33). The link held after adjusting for the usual cardiovascular risk factors, suggesting bone density is tracking something beyond the heart-disease story your standard labs tell.

Other Disease Associations

Low femoral neck Z-scores show up disproportionately in specific populations. About 22.5% of adults with arthrogryposis multiplex congenita had a Z-score below -2 at the hip. In Norwegian elite Para athletes, 29% had a Z-score of -2 or lower at the spine or femoral neck. Roughly 36% of patients with axial spondyloarthritis showed low BMD at the femoral neck or total hip, with younger age and inflammatory sacroiliitis driving the signal.

Lower femoral neck BMD has also been linked to a higher risk of dementia in older adults, to liver fibrosis in people with metabolic dysfunction-associated fatty liver disease and type 2 diabetes, and to inflammatory markers like soluble IL-6 receptor (a signal of chronic inflammation).

Reference Ranges

These categories are based on published interpretations of adult Z-scores. They are orientation, not absolute targets. Different DXA machines and reference populations can give slightly different numbers, and pediatric and ethnic-specific ranges exist that may shift cutpoints.

Z-ScoreInterpretationWhat It Suggests
Above -1.0Within expected rangeYour hip bone strength is consistent with peers your age and sex.
-1.0 to -2.0Below averageBone density is lower than typical. Worth investigating, especially with risk factors.
At or below -2.0Below expected rangeStrongly suggests a secondary cause of bone loss. Workup and likely treatment are warranted.

For comparison within yourself, the most meaningful trend is one done on the same DXA machine at the same facility. Switching scanners can change a Z-score by enough to mimic real biological change when nothing has shifted.

Tracking Your Trend

A single Z-score is a snapshot. Your skeleton changes slowly, so the real value comes from watching the trajectory across years. DXA precision matters: small shifts can fall inside the noise of the measurement, which is why most experts recommend repeat scans no sooner than 12 to 24 months apart unless you are on aggressive therapy or expecting rapid change.

A reasonable cadence for someone tracking proactively is a baseline scan in your 40s if you have any risk factors, repeat scanning every 1 to 2 years if your number is borderline or you are intervening, and at least every 2 years once you cross into the postmenopausal years or hit your 60s as a man.

What an Abnormal Result Should Make You Do

A Z-score at or below -2 is a flag for a secondary cause of bone loss, not a closed verdict. The standard next step is bloodwork to look for the most common drivers: vitamin D (25-hydroxy), calcium, parathyroid hormone (a hormone that controls calcium balance), thyroid stimulating hormone, kidney function, and bone turnover markers like CTX (a fragment released when bone is broken down) or bone-specific alkaline phosphatase (an enzyme that rises when bone is being built).

If those tests reveal a treatable cause, fixing it can move the Z-score. If they do not, an endocrinologist or bone specialist can help decide whether antiresorptive or anabolic therapy is appropriate. People at moderate risk should also use a fracture risk calculator like FRAX to integrate BMD with age, weight, and clinical risk factors into a 10-year fracture probability.

When Results Can Be Misleading

DXA at the hip is reliable but not perfect. A few things can distort a single reading:

  • Positioning and machine differences: small variations in how your leg is rotated, or scanning on a different DXA machine than last time, can shift your number enough to imitate real change.
  • Recent imaging contrast or supplements: barium from a recent GI study or high-dose calcium taken right before the scan can artificially inflate density.
  • Severe arthritis or hardware in the hip: degenerative changes can falsely raise density at the spine more than hip, but hip implants or fractures on one side make that side unusable.
  • Race-based reference databases: some scanners still apply race-adjusted norms, which can either over- or underestimate fracture risk depending on the population.

A Note on T-Score vs Z-Score

If you are postmenopausal or a man over 50, your treatment decisions are usually anchored to the T-score, not the Z-score, because the diagnostic criteria for osteoporosis use the young-adult reference. The Z-score still adds value by flagging whether your loss is faster than expected for your age, which points toward secondary causes worth chasing.

What Moves This Biomarker

Evidence-backed interventions that affect your BMD Z-Score (Left Femoral Neck) level

Increase
Denosumab
Denosumab is an injectable antibody that blocks the cells that resorb bone. In a network meta-analysis, denosumab was the most effective drug for raising spine BMD and was also effective at the femoral neck. After 1 year of denosumab in postmenopausal women, alendronate maintained the gains, but stopping denosumab without follow-on therapy causes rapid BMD loss and increased vertebral fracture risk.
MedicationStrong Evidence
Increase
Romosozumab
Romosozumab is a monthly injection that both builds bone and blocks resorption. In a randomized phase 3 trial of 436 women transitioning off bisphosphonates, romosozumab produced larger hip BMD gains than teriparatide. In the FRAME trial extension, 12 months of romosozumab followed by denosumab reduced fracture risk and increased BMD in Japanese women at high fracture risk.
MedicationStrong Evidence
Increase
Teriparatide (parathyroid hormone analog)
Teriparatide is a daily injection that stimulates new bone formation. A Bayesian network meta-analysis in men found teriparatide was the top choice for lumbar spine BMD and overall safety, while alendronate was strongest at the femoral neck specifically. In glucocorticoid-induced osteoporosis, teriparatide and denosumab outperformed bisphosphonates for raising BMD and reducing vertebral fractures.
MedicationStrong Evidence
Decrease
Long-term systemic glucocorticoids (e.g., prednisone)
Glucocorticoids genuinely damage bone by suppressing bone-forming cells, increasing bone resorption, and reducing calcium absorption. In children and adolescents with secondary osteoporosis, higher cumulative glucocorticoid dose was tied to lower BMD and more vertebral fractures. In adults with congenital adrenal hyperplasia on long-term steroids, BMD was significantly lower than controls. This is a true cause of secondary osteoporosis, not a lab artifact.
MedicationStrong Evidence
Increase
Bisphosphonates (alendronate, risedronate, zoledronic acid)
Bisphosphonates raise femoral neck BMD over months to years by slowing the cells that break down bone, which translates into measurable Z-score improvement. A network meta-analysis of randomized trials found bisphosphonates significantly improved hip and femoral neck BMD and reduced fragility fracture risk in postmenopausal women. They are the most commonly prescribed first-line treatment for osteoporosis.
MedicationModerate Evidence
Increase
Hormone replacement therapy (estrogen)
Estrogen slows the bone resorption that accelerates after menopause. In a randomized trial of 121 young oligo- or amenorrheic athletes, 12 months of transdermal estradiol improved bone mineral density compared with an oral contraceptive pill. In a 25-year follow-up of 3,222 postmenopausal women, HRT use was associated with less long-term femoral neck bone loss.
MedicationModerate Evidence
Increase
Resistance training, especially high-load
Targeted resistance training stresses bone enough to stimulate new bone formation, with effects that build over months. A meta-analysis in postmenopausal women found resistance training improved BMD at the lumbar spine, femoral neck, and total hip, with the strongest effects from high-intensity training over longer durations. Mind-body exercise also improved spine and femoral neck BMD in osteoporotic and osteopenic adults.
ExerciseModest Evidence
Increase
Combined calcium and vitamin D
Calcium and vitamin D together raise BMD modestly and reduce hip fracture risk in postmenopausal women, especially in people with low baseline intake or vitamin D deficiency. A meta-analysis of randomized controlled trials confirmed BMD gains and reduced hip fractures. In a 3-year randomized trial of 5,286 women aged 65 to 71, daily supplementation positively affected BMD in women with adequate calcium intake.
SupplementModest Evidence
Decrease
Long-term proton pump inhibitor use
PPIs (proton pump inhibitors, drugs that suppress stomach acid like omeprazole) can reduce calcium absorption with long-term use. In a study of men over 70, prolonged PPI use was associated with lower BMD, while H2 blockers showed no such association. A 2024 analysis found chronic PPI use was associated with reduced bone density and quality in men but not women. The effect is real but smaller than glucocorticoids.
MedicationModest Evidence

Frequently Asked Questions

References

28 studies
  1. Romand X, Gastaldi R, Pérennou D, Baillet a, Dieterich KScientific Reports2024
  2. Sandboge S, Kuula J, Björkqvist J, Hovi P, Mäkitie O, Kajantie EPaediatric and Perinatal Epidemiology2022
  3. Mersebach H, Johansson J, Rasmussen Å, Bengtsson B, Rosenberg K, Hasholt L, Sørensen S, Feldt-rasmussen UGenetics in Medicine2007
  4. Theander L, Willim M, Nilsson J, Karlsson M, ÅKesson K, Jacobsson L, Turesson CRMD Open2020
  5. Koivisto-mørk a, Steffen K, Finnes TE, Pretorius M, Berge HMFrontiers in Sports and Active Living2023